Transitioning to cutaquig

Choosing SCIg as your PI treatment for adults

You have choices for treating your primary immunodeficiency (PI) disease for adults.1 Subcutaneous immunoglobulin therapy (or SCIg) is an option. Infusing PI medication under the skin—instead of into a vein, which is known as intravenous immunoglobulin therapy (or IgIV)—offers key benefits. For example, SCIg therapy gives you the option to self-administer PI medication at home, work, or on the go—so you won’t have to visit your healthcare provider or a hospital for treatment.2-4

Whether you’re new to SCIg or transitioning from your current PI treatment to cutaquig, it’s important to work closely with your healthcare provider for instruction and guidance.1

Switching from another SCIg treatment to cutaquig

If you’re currently using SCIg therapy to treat your PI disease for adults, switching to cutaquig is a straightforward process. In most cases, your dosing and self-administration schedule will be the same.1 Team up with your healthcare provider to properly manage the transition.

Transitioning from IgIV to SCIg with cutaquig

If you’re currently using IgIV therapy to treat your PI disease for adults, switching to SCIg therapy with cutaquig involves a specific process. Your healthcare provider must give you instruction and guidance to properly manage the transition.1

With SCIg therapy, you’ll have the option to self-administer cutaquig—but only after you’ve received training from your healthcare provider.1

Things to consider as you transition to cutaquig

Here are important things to consider as you transition to cutaquig, whether from another SCIg treatment or an IgIV treatment:

  • Make sure you are financially covered
  • Receive your infusion equipment
    • Get the necessary equipment—plus, associated explanations and training—from your healthcare provider or specialty pharmacy
  • Get training for self-administration
    • You must receive proper training from your healthcare provider before you try the option to self-administer cutaquig1
  • Register to receive your cutaquig Patient Welcome Kit and view its contents, including:
    • A cutaquig Patient Handbook featuring:
      • Introductory information about cutaquig
      • An Infusion Guide to get you started right
      • Tips, insights, and advice for living with PI
      • FAQs about cutaquig
      • Details about the IgCares program and its many benefits
    • An Infusion Journal for tracking your treatment
    • A Reimbursement Card to help you save money on prescriptions
    • An Information Card to keep your dosage and healthcare provider details handy
Patient Welcome Kit Box Cover Image
icon-clip-board Created with Sketch.

Patient Welcome Kit

Register to receive your cutaquig Patient Welcome Kit
References:
  1. Cutaquig® [package insert]. Lachen, Switzerland: Octapharma AG; 2018.
  2. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097.
  3. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287.
  4. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference December 10, 2015. http://www.igliving.com/life-with-ig/teleconference/advantages-and-disadvantages-of-intravenous-and-subcutaneous-immune-globulin-therapy.html. Accessed April 25, 2019.